Overview
Breakthroughs for Obese Patients with VTE
The Expert Circle: Navigating the Expanding Therapeutic Benefits of DOACs
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
What is the latest evidence for VTE prophylaxis and treatment in obese patients and how is this different from the current guidelines? In this activity, expert cardiology faculty cover the most recent data and guideline limitations on VTE prevention and management. Roundtable discussion is included to provide practical insight to help clinicians apply knowledge to their practice.
This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hematologists and primary care physicians.
The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their obese patients. Learners post-activity will also be better able to discuss limitations of various VTE guideline recommendations for obese patients in the context of recent evidence as well as interpret the latest data on DOACs as to develop VTE prophylaxis and treatment plans for these patients.
Upon completion of this activity, participants will be able to:
• Optimize anticoagulant therapy prophylactically and therapeutically in obese patients
• Discuss limitations of various guideline recommendations for prophylactic and therapeutic anticoagulation in obese patients in the context of recent evidence
• Interpret the latest data on DOACs for treating and protecting against thrombotic events in obese patients
• Optimize anticoagulant therapy prophylactically and therapeutically in obese patients
• Discuss limitations of various guideline recommendations for prophylactic and therapeutic anticoagulation in obese patients in the context of recent evidence
• Interpret the latest data on DOACs for treating and protecting against thrombotic events in obese patients
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
Gregory Piazza, MD, MS
Associate Professor of Medicine
Harvard Medical School
Staff Cardiologist, Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
Christian T. Ruff, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this activity.
The following financial relationships have been provided:
Gregory Piazza, MD, MS
Consulting: Agile, Amgen, Boston Scientific Corporation, Pfizer
Grants: Bayer, Bristol Myers Squibb, Boston Scientific Corporation, Janssen, Portola
Christian Ruff, MD, MPH
Grants/Research Support (through institution): Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo
Honoraria: Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer, Portola
Grants/Research Support (through TIMI Study Group): Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, The Medicines Company, Zora Biosciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.